Thalidomide UK, an organisation representing people harmed by the drug Thalidomide, has submitted a formal complaint to the Charity Commission about serious management failures at The Thalidomide Trust, the charity set up to support the Thalidomide community.
The complaint
This outlines what Thalidomide UK describes as “deep seated problems” in the Trust. For too long, the Trust has believed it is a charity doling out favours to a disabled community. Whereas it is, and always was, a vehicle to manage a compensation fund for those severely impacted by the effects of thalidomide. This was the drug distributed by Distillers to pregnant women in the 1960s. It’s now owned by multi-million-pound drinks company, Diageo.
Matters have now come to a head for many of those affected by this toxic drug. Thalidomide UK says the relationship between many beneficiaries and the Trust has deteriorated significantly. They report amongst other issues that:
• The concerns of beneficiaries are routinely dismissed or minimised. They have often been treated with disdain and disparagement by the very persons who are charged with their welfare. It is a shocking display of the worst kind of patronising conduct on the part of those who should know better.
• The Trust refuses to engage constructively with legitimate concerns.
• The Trust’s leadership has created a culture where criticism is shut down rather than addressed, leaving beneficiaries feeling excluded from decisions that directly affect their lives.
• The lack of transparency over key research projects affecting their health and wellbeing
• They have been deprived of their long-standing ability to have input into the governance of the Trust;
• Failure to safeguard vulnerable beneficiaries.
In effect, the Trust has stopped listening to the people it exists to support.
Action sought
It has now become imperative and important to challenge this Board of Trustees by a referral to the Charity Commission. Thalidomide UK is asking the Charity Commission to open a statutory inquiry into the Trust’s governance, leadership, and handling of beneficiary concerns
Kim Fenton, President of Thalidomide UK, says:
“This complaint is the result of long-standing concerns that have been ignored for far too long. The Trust is supposed to protect and support us, yet it has become defensive, secretive, and unwilling to listen. I didn’t battle for years with Guinness and then Diageo to end up in the position we are now, where many beneficiaries are ignored or worse, bullied. Beneficiaries deserve a charity that is transparent, accountable, and genuinely committed to their wellbeing. Right now, that is not what we are experiencing.
The Charity Commission cannot simply look the other way or treat this as a routine internal disagreement. Beneficiaries, who have spent decades fighting for basic dignity, care, and medical survival, deserve a board that operates transparently and strictly within the law.
We are asking the Charity Commission to step in because the Trust’s leadership has failed to address serious issues raised repeatedly by the people who rely on it. This is not a minor squabble. It is a fundamental breakdown in governance and accountability.”
